Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study
David Nanchen, David Carballo, Stefan Bilz, Hans Rickli, Konstantinos C Koskinas, François Mach, Christian Mueller, Carmela Crljenica, Mariagrazia Rossi, Nina Reichert & Isabella Sudano
In real-world clinical practice, evolocumab was mainly used in patients with statin intolerance and pre-existing CVD. In this population, adherence to evolocumab and low LDL-C levels were maintained over 1 year, with better LDL-C goal achievement in patients using evolocumab in combination with other lipid-lowering drugs. Safety of evolocumab was similar to that documented in randomized controlled trials.
|citation||Nanchen D, Carballo D, Bilz S, Rickli H, Koskinas K C, Mach F, Mueller C, Crljenica C, Rossi M, Reichert N, Sudano I. Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. Adv Ther 2021; 39:504-517.|
|type||journal paper/review (English)|
|date of publishing||18-11-2021|
|journal title||Adv Ther (39/1)|